

www.tajpharma.com

Zulritan® Cytarabine 100 mg/ml Injection

Each 1 ml contains 100 mg of cytarabine

Zulritan® Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord).



Zulritan®  
(cytarabine) Injection  
20mg/mL

**HOW Zulritan® CYTARABINE IS GIVEN:**

Zulritan® CYTARABINE MAY BE GIVEN AS AN INFUSION INTO THE VEIN (INTRAVENOUS OR IV). ANOTHER METHOD IT IS GIVEN IS BY INTRATHECAL INFUSION. THIS METHOD IS USED WHEN DRUGS NEED TO REACH THE CEREBROSPINAL FLUID (CSF) THE FLUID THAT IS SURROUNDING THE BRAIN AND SPINAL CORD, THE DRUG IS INFUSED DIRECTLY INTO THE SPINAL FLUID. THERE IS NO PILL FORM OF Zulritan® CYTARABINE.



Zulritan®  
(cytarabine) Injection  
20mg/mL

**LIFE WILL WIN  
AT TAJ PHARMA INDIA.**

**Zulritan® Cytarabine is used alone or with other medications to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.**

Cytarabine may be used **alone or in combination with other antineoplastic agents. It is indicated alone or in combination for induction of remission and/or maintenance in patients with acute myeloid leukaemia, acute non-lymphoblastic leukaemias, acute lymphoblastic leukaemias, acute lymphocytic leukaemia, erythroleukaemia, blast crises of chronic myeloid leukaemia, diffuse histiocytic lymphomas (non-Hodgkin's lymphomas of high malignancy), meningeal leukaemia and meningeal neoplasms.** Clinicians should refer to the current literature on combination therapy before initiating treatment.

Cytarabine Injection can be diluted with Sterile Water for Injections BP, Glucose Intravenous Infusion BP or Sodium Chloride Intravenous Infusion BP. Prepared infusions, in the recommended diluents, should be used immediately. Alternatively, the diluted infusion fluids may be stored at 2-8°C, protected from light, but portions remaining unused after 24 hours must be discarded.

**Remission Induction: Adults**

**Continuous Dosing:** The usual dose in leukaemia is 2 mg/kg by rapid intravenous injection daily for ten days. If after ten days neither therapeutic response nor toxicity has been observed, the dose may be increased to 4 mg/kg until a therapeutic response or toxicity is evident. Daily blood counts should be taken. Almost all patients can be carried to toxicity with these doses. Alternatively, 0.5 to 1 mg/kg may be infused daily in 1-24 hours for ten days, and then at a rate of 2 mg/kg/day until toxicity is observed. Continue to toxicity or until remission occurs. Results from one hour infusions have been satisfactory in the majority of patients.

**Intermittent dosing:** Cytarabine may be given as intermittent intravenous doses of 3-5 mg/kg daily, for five consecutive days. This course of treatment can be repeated after an interval of 2 to 9 days and repeated until the therapeutic response or toxicity is exhibited.

**Pack sizes 1's, 5's, 10's and 20's.**

**Food and Drug Administration (FDA) approved .Prescription Only (POM)**

**A Taj Pharma India Product**

**DO NOT THROW AWAY ANY MEDICINES VIA WASTEWATER OR HOUSEHOLD WASTE. ASK YOUR PHARMACIST HOW TO THROW AWAY MEDICINES YOU NO LONGER USE. THESE MEASURES WILL HELP PROTECT THE ENVIRONMENT.**

**CAUTION: CONTACT YOUR HEALTH CARE PROVIDER IMMEDIATELY, DAY OR NIGHT, IF YOU SHOULD EXPERIENCE ANY OF THE FOLLOWING SYMPTOMS: FEVER OF 100.4°F (38°C) OR HIGHER OR CHILLS (POSSIBLE SIGNS OF INFECTION), CHEST PAIN OR HEART PALPITATIONS, INABILITY TO PASS URINE**



**TAJ**  
PHARMA®  
A TAJ Enterprise

**Do not store above 25°C. Keep container in the outer carton, in order to protect from light.**